Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Greaves, Ronda / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter


IMPACT FACTOR 2018: 3.638

CiteScore 2018: 2.44

SCImago Journal Rank (SJR) 2018: 1.191
Source Normalized Impact per Paper (SNIP) 2018: 1.205

Online
ISSN
1437-4331
See all formats and pricing
More options …
Volume 38, Issue 9

Issues

Angiotensin I-Converting Enzyme Gene Polymorphism and Drug Response

Bruno Baudin
Published Online: 2005-06-01 | DOI: https://doi.org/10.1515/CCLM.2000.123

Abstract

An insertion/deletion (I/D) polymorphism of the angiotensin I-converting enzyme (ACE) gene has been described in chromosome 17q23 of the human genome. Subjects with the genotype DD have markedly higher plasma ACE levels than those with genotype II; although ACE concentration in plasma is not rate-limiting for the production of angiotensin II, it has been suggested that the renin-angiotensin system may have an enhanced role in cardiovascular homeostasis in subjects with DD genotype or D allele. Metaanalysis confirmed the association of the D allele with an increased risk of myocardial infarction and stroke, but these relations are still uncertain with longevity and renal deterioration. Otherwise, I allele seems to be related with an improved response to physical training. The I/D polymorphism of the ACE gene is not a marker for any form of hypertension, though some conflicting results have been described. Nevertheless this polymorphism may have an influence on the antihypertensive response, particularly when using ACE inhibitors (ACEI). For example, blood pressure normalization with captopril in patients suffering from cardiac failure would be more effective in II genotype; conversely, both regression in left ventricular hypertrophy and improvement in diastolic filling would be greater after long-term treatment with enalapril in patients with essential hypertension and DD genotype. Conflicting results were also described using ACEI as a renoprotective therapy. This review therefore supports the justification for further evaluation in appropriately powered studies.

About the article

Published Online: 2005-06-01

Published in Print: 2000-09-18


Citation Information: Clinical Chemistry and Laboratory Medicine, Volume 38, Issue 9, Pages 853–856, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/CCLM.2000.123.

Export Citation

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Eiichi GESHI, Tomomi KIMURA, Mika YOSHIMURA, Hiroshi SUZUKI, Shinji KOBA, Tetsuo SAKAI, Tsukasa SAITO, Atsuro KOGA, Masaaki MURAMATSU, and Takashi KATAGIRI
Hypertension Research, 2005, Volume 28, Number 9, Page 719
[2]
Ioannis E. Vasileiadis, Christos A. Goudis, Pinelopi T. Giannakopoulou, and Tong Liu
COPD: Journal of Chronic Obstructive Pulmonary Disease, 2018, Page 1
[3]
Sender Lkhagvadorj, Long Qu, Weiguo Cai, Oliver P. Couture, C. Richard Barb, Gary J. Hausman, Dan Nettleton, Lloyd L. Anderson, Jack C. M. Dekkers, and Christopher K. Tuggle
American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2010, Volume 298, Number 2, Page R494
[4]
Robert B. Yates and Mark Stafford-Smith
Seminars in Cardiothoracic and Vascular Anesthesia, 2006, Volume 10, Number 4, Page 314
[5]
Gwan Gyu Song, Jae-Hoon Kim, and Young Ho Lee
Journal of the Renin-Angiotensin-Aldosterone System, 2015, Volume 16, Number 1, Page 211
[6]
Gwan Gyu Song, Jae-Hoon Kim, and Young Ho Lee
Journal of the Renin-Angiotensin-Aldosterone System, 2015, Volume 16, Number 1, Page 219
[7]
Farzad Heidari, Ramachandran Vasudevan, Siti Zubaidah Mohd Ali, Patimah Ismail, Ali Etemad, Seyyed Reza Pishva, Fauziah Othman, and Suhaili Abu Bakar
Journal of the Renin-Angiotensin-Aldosterone System, 2015, Volume 16, Number 4, Page 872
[8]
Haralampos J Milionis, Michael S Kostapanos, Konstantinos Vakalis, Ioanna Theodorou, Ioanna Bouba, Rigas Kalaitzidis, Ioannis Georgiou, Moses S Elisaf, and Kostas C Siamopoulos
Journal of the Renin-Angiotensin-Aldosterone System, 2007, Volume 8, Number 4, Page 181
[9]
Xiaotao Li, Yanmei Du, Yanfang Du, and Xizheng Huang
Journal of Cardiovascular Pharmacology and Therapeutics, 2003, Volume 8, Number 1, Page 25
[10]
Hsiao-Han Wang, Chi-Chih Hung, Daw-Yang Hwang, Mei-Chuan Kuo, Yi-Wen Chiu, Jer-Ming Chang, Jer-Chia Tsai, Shang-Jyh Hwang, Julian L. Seifter, Hung-Chun Chen, and Emmanuel A. Burdmann
PLoS ONE, 2013, Volume 8, Number 7, Page e67140
[11]
Bruno Baudin
Experimental Physiology, 2005, Volume 90, Number 3, Page 277
[12]
Bing Niu, Yuchao Zhang, Juan Ding, Yin Lu, Miao Wang, Wencong Lu, Xiaochen Yuan, and Jinyuan Yin
Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 2014, Volume 1844, Number 1, Page 214
[14]
A. Chalghoum, Y. Noichri, L. Chkioua, I. Gammoudi, A. Dandana, H. Chahed, S. Khelil, G. Jeridi, B. Baudin, S. Ferchichi, and A. Miled
Annales de Cardiologie et d'Angéiologie, 2011, Volume 60, Number 3, Page 135
[15]
Fu-Mei Chung, Tien-Yu Shieh, Yi-Hsin Yang, Dao-Ming Chang, Shyi-Jang Shin, Jack C.-R. Tsai, Tony Hsiu-hsi Chen, Tong-Yuan Tai, and Yau-Jiunn Lee
Translational Research, 2007, Volume 150, Number 1, Page 58
[16]
Brigitta Bondy, Thomas C. Baghai, Peter Zill, Cornelius Schule, Daniela Eser, Tobias Deiml, Peter Zwanzger, Robin Ella, and Rainer Rupprecht
Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2005, Volume 29, Number 6, Page 1094
[17]
Gere Sunder-Plassmann, Harald Kittler, Corinna Eberle, Michael M. Hirschl, Christian Woisetschläger, Ulla Derhaschnig, Anton N. Laggner, Walter H. Hörl, and Manuela Födinger
Critical Care Medicine, 2002, Volume 30, Number 10, Page 2236
[18]
Menno J.A. Kocks, Dick de Zeeuw, and Gerjan J. Navis
Current Opinion in Nephrology and Hypertension, 2002, Volume 11, Number 2, Page 135
[19]
Bruno Baudin
Clinical Chemistry and Laboratory Medicine, 2002, Volume 40, Number 3
[20]
Giuseppe Bianchi, Jan A Staessen, and Ferrari Patrizia
Pharmacogenomics, 2003, Volume 4, Number 3, Page 279
[21]
[22]
Gysèle S. Bleumink, Anna F.C. Schut, Miriam C.J.M. Sturkenboom, Cornelia M. van Duijn, Jaap W. Deckers, Albert Hofman, J. Herre Kingma, Jacqueline C.M. Witteman, and Bruno H Ch. Stricker
Pharmacogenetics and Genomics, 2005, Volume 15, Number 2, Page 75
[23]
D Ghosh, M A Skinner, and W A Laing
European Journal of Clinical Nutrition, 2007
[24]
Y Bae, C Park, J Han, Y-J Hong, H-H Song, E-S Shin, J-E Lee, B-G Han, Y Jang, D-J Shin, and S K Yoon
Journal of Human Hypertension, 2007, Volume 21, Number 2, Page 159
[25]
Seok Hwee Koo and Edmund Jon Deoon Lee
Clinical and Experimental Pharmacology and Physiology, 2006, Volume 33, Number 5-6, Page 525
[26]
T. Schröder, F. Sachse, and C. Rudack
HNO, 2005, Volume 53, Number 5, Page 459

Comments (0)

Please log in or register to comment.
Log in